{
  "disease_name": "Krabbe disease",
  "disease_id": "krabbe_disease",
  "pathogen_type": "genetic",
  "pathogen": "GALC gene deficiency (galactosylceramidase)",
  "target_classes": [
    "GALC_enzyme_replacement",
    "substrate_reduction_therapy",
    "oligodendrocyte_protector"
  ],
  "primary_endpoints": [
    "psychosine_level_reduction",
    "nerve_conduction_velocity_preservation",
    "developmental_milestone_achievement",
    "GALC_enzyme_activity_restoration"
  ],
  "efficacy_threshold": 0.35,
  "ic50_max_um": 1.0,
  "ic50_optimal_um": 0.1,
  "selectivity_index_min": 50.0,
  "cc50_min_um": 100.0,
  "toxicity_threshold": 0.015,
  "molecular_weight_max": 600.0,
  "logp_min": -2.0,
  "logp_max": 4.0,
  "hbd_max": 6,
  "hba_max": 12,
  "lipinski_violations_max": 2,
  "admet_score_min": 0.6,
  "prv_eligible": true,
  "regulatory_pathway": "PRV_ACCELERATED",
  "constraint_version": "1.0.0",
  "constitutional_compliance": {
    "L51_zero_gaps": true,
    "L10_harm_absolute": true,
    "L9_axiomatic_grounding": true,
    "L5_transparency": true,
    "L11_toxicity_hard_limit": true
  }
}
